In Nature Communications, Weidle, Brunette, Wrenn and colleagues reported a pan-Ebolavirus nanoparticle vaccine that protected rodents against lethal infections from both Zaire and Sudan virus species. The preclinical study addresses the multi-species challenge that complicates vaccine coverage for filovirus outbreaks. For vaccine developers, the key point is demonstrating cross-species protection using a single platform design rather than species-specific constructs. Follow-on work will need to establish durability, dosing schedules, and translational biomarkers for immune response in more clinically relevant models.